

# Paxlovid in the treatment of COVID-19

<b>Submission date</b> 09/03/2023	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 18/03/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 10/10/2023	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Since the COVID-19 outbreak, the treatment of patients with COVID-19 pneumonia has been an issue of concern. At present, there is no specific drug for COVID-19, only symptomatic treatment, and the treatment of moderate and severe patients is a major difficulty. The emergence of nirmatavir/ritonavir tablets (Paxlovid™) has brought new hope for the treatment of COVID-19 and has shown an effective inhibitory effect on the Omicron variant of COVID-19.

### Who can participate?

Patients aged 12 years and over infected with the Omicron variant of COVID-19

### What does the study involve?

Patients were retrospectively collected and divided into two groups according to the treatment regimen. Patients in both groups were given Lianhua Qingwen Capsule orally, three times/day, 6 g/time. The study group was given nirmatrelvir 300 mg/ritonavir 100 mg orally, every 12 hours, for 5 days, and the control group was not given any antiviral drugs. The two groups were compared in terms of the change in COVID-19 tests, hospitalization time and adverse drug reactions.

### What are the possible benefits and risks of participating?

The study could play an important guiding role in the treatment of the COVID-19 Omicron variant in the future, and reduce the pain and disease burden of patients.

### Where is the study run from?

Wenzhou Central Hospital (China)

### When is the study starting and how long is it expected to run for?

January 2022 to December 2022

### Who is funding the study?

Investigator initiated and funded

### Who is the main contact?

Chaochao Qiu, 790485628@qq.com

# Contact information

## Type(s)

Principal investigator

## Contact name

Mr Chaochao Qiu

## Contact details

No. 252, Baili East Road

Lucheng District

Wenzhou City

China

325000

+86 (0)86718290

790485628@qq.com

# Additional identifiers

## Clinical Trials Information System (CTIS)

Nil known

## ClinicalTrials.gov (NCT)

Nil known

## Protocol serial number

Nil known

# Study information

## Scientific Title

Paxlovid in the treatment of COVID-19

## Acronym

PIT

## Study objectives

The efficacy of nirmatrelvir/ritonavir in the treatment of the Omicron variant of COVID-19 was positive and had good tolerance in patients

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 14/11/2022, Ethics Committee of Wenzhou Central Hospital (252 Baili Dong Lu, Lucheng District, Wenzhou City, Zhejiang Province, China; +86 (0)577 88070000; weybgs@163.com), ref: L2022-04-082

## Study design

Retrospective study

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

COVID-19 (SARS-CoV-2 infection)

## Interventions

58 cases infected with the Omicron variant of COVID-19 were retrospectively collected and divided into two groups according to the treatment regimen. Patients in both groups were given Lianhua Qingwen Capsule orally, three times/day, 6 g/time. The study group was given nirmatrelvir 300 mg/ritonavir 100 mg orally, q12h, for 5 days, and the control group was not given any antiviral drugs. The two groups were compared in terms of the change in CT values of COVID-19 nucleic acid, the negative conversion time of COVID-19 RNA, hospitalization time, adverse drug reactions, and COVID-19 nucleic acid re-positive.

## Intervention Type

Drug

## Phase

Phase III/IV

## Drug/device/biological/vaccine name(s)

Nirmatrelvir/ritonavir

## Primary outcome(s)

CT values (CT values of 40 for negative results) of nasal swab COVID-19 nucleic acid tests on days 4, 7, 9 and 11 of treatment

## Key secondary outcome(s)

1. First negative conversion time (or CT value  $\geq 40$ ) of COVID-19 nucleic acid tests
2. Hospitalization time, strictly according to discharge criteria
3. Adverse drug reactions recorded during hospitalization
4. COVID-19 nucleic acid re-positive in daily COVID-19 nucleic acid tests in the 7 days of isolation after discharge

## Completion date

31/12/2022

## Eligibility

### Key inclusion criteria

1. Confirmation of COVID-19 infection within 24 h and positive nasopharyngeal swab for COVID-19 nucleic acid RNA
2. Age  $\geq 12$  years and weight  $\geq 40$  kg
3. Subjects of fertility must agree to use highly effective contraceptive methods

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Sex**

All

**Total final enrolment**

58

**Key exclusion criteria**

1. Previous history of COVID-19 treatment
2. A known history of active liver disease
3. Patients on renal dialysis or have moderate to severe impaired renal function
4. The known human immunodeficiency virus (HIV) infection
5. Suspected or confirmed concurrent active systemic infections other than COVID-19 infection
6. Allergy or other contraindication to any component of the study intervention
7. Any drug or substance that is currently or expected to be used that is a high reliance on CYP3A4 enzyme clearance or strong CYP3A4 enzyme inducers
8. Pregnant or breastfeeding women

**Date of first enrolment**

15/11/2022

**Date of final enrolment**

30/12/2022

**Locations****Countries of recruitment**

China

**Study participating centre**

**Wenzhou Central Hospital**

No. 252, Baili East Road

Lucheng District

Wenzhou City

China

325000

**Sponsor information**

**Organisation**

Wenzhou Central Hospital

**ROR**

<https://ror.org/00w5h0n54>

**Funder(s)****Funder type**

Other

**Funder Name**

Investigator initiated and funded

**Results and Publications****Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study will be stored in a publicly available repository

**IPD sharing plan summary**

Stored in publicly available repository

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		13/07/2023	10/10/2023	Yes	No